Search clinical trials for: programmed cell death protein 1 (PD-1)

Total 105888 results

Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Merck Sharp & Dohme LLC

Recruiting

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Melanoma | Lymphoma | Solid Tumor | Classical Hodgkin Lymphoma | Microsatellite-instability-high Solid Tumor

France, Germany, Italy, Netherlands, Sweden, United Kingdom, Brazil, Israel, Korea, Republic of, United States
Fudan University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Hepatocellular Carcinoma

China
Merck KGaA, Darmstadt, Germany
Merck N.V.-S.A., Belgium

Terminated

An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen

Multifollicular Stimulation

Belgium
Diwakar Davar
Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Squamous Cell Carcinoma

United States
The Affiliated Hospital of Qingdao University

Unknown

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Chang Gung Memorial Hospital

Unknown

WGA in Platinum-refractory HNSCC Underwent Nivolumab

HNSCC

Taiwan
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
RenJi Hospital

Recruiting

A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC

Fumarate Hydratase Deficient Renal Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Uro-1 Medical

Recruiting

Use of Repris Needle in Bladder Injection

Overactive Bladder Syndrome

United States
Uro-1 Medical

Recruiting

Assessment of VMCore Biopsy Versus Standard of Care Biopsy

Prostate Cancer

United States
Alpha-1 Foundation

Recruiting

Alpha-1 Research Registry

Alpha 1-Antitrypsin Deficiency

United States
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
Fuzhou General Hospital

Unknown

Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.

Small Cell Lung Cancer | Lung Neoplasm | PD-1 Inhibitors

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
Women's Hospital School Of Medicine Zhejiang University

Recruiting

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Gestational Trophoblastic Neoplasia

China
Centre hospitalier de l'Université de Montréal...
Bristol-Myers Squibb

Completed

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Melanoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Brain Metastases, Adult | Clear-Cell Metastatic Renal Cell Carcinoma

Canada
Beijing Friendship Hospital

Completed

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Biliary Tract Cancer | Capecitabine | Targeted Molecular Therapy | Anti-PD-1 Therapy

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ACCLAIM)

NSCLC | PD-1

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China
Chinese PLA General Hospital

Unknown

Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.

Solid Tumor, Adult

China
Huazhong University of Science and Technology

Unknown

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

HCC

China
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Sun Yat-sen University

Recruiting

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Lung Cancer Stage II
National Cancer Institute (NCI)

Completed

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin Lymphoma | Primary Central Nervous System Lymphoma | Gray-zone Lymphoma

United States
Shimousa Hematology Study Group
Epidemiological and Clinical Research Information Network

Unknown

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Chronic Myeloid Leukemia

Japan
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Crozer-Keystone Health System
Saint Peters University Hospital; Community Medical Center, Toms River, NJ

Completed

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect (I-SABR)

Non Small Cell Lung Cancer | Metastatic Nonsmall Cell Lung Cancer

United States
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Carcinoma, Renal Cell

China
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Non-small Cell Lung Carcinoma
Taiho Pharmaceutical Co., Ltd.

Completed

Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer

Gastric Cancer

Japan
NYU Langone Health
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer (SCLC)

United States
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Kitasato University
Yokohama City University Medical Center; St. Marianna University School of... and other collaborators

Unknown

Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

Hypertension | Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru
Shanghai Ninth People's Hospital Affiliated to...
Fudan University; First Affiliated Hospital of Fujian Medical University; Tianjin... and other collaborators

Recruiting

Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) (IMPORT)

Head and Neck Squamous Cell Carcinoma

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Xuhua Duan

Recruiting

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

NSCLC

China
Gazi University
Hacettepe University; Cukurova University; Marmara University; Istanbul University and other collaborators

Unknown

Evaluation of Status of Early Reached Target Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children (ERTENIFABPICU)

Enteral Nutrition | Feeding Intolerance | Intestinal Fatty Acid Binding Protein

Germany

Search clinical trials for: programmed cell death protein 1 (PD-1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations